Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

Randomized Phase 2 Clinical Trial of Pembrolizumab Combined with Bevacizumab with or without Agonist Anti-CD40 CDX-1140 in Patients with Recurrent Ovarian Cancer

Principal Investigator: Zsiros, Emese

2215-CL-0203 A Phase 1/2, Multicenter, Open-Label, Randomized, Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients with Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) not Eligible for…

Principal Investigator: Wang, Eunice S

(EA7222) A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas

Principal Investigator: Gupta, Ajay

A Study of PARG Inhibitor IDE161 in Participants with Advanced Solid Tumors ( IDE161-001)

Principal Investigator: Fountzilas, Christos

A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Principal Investigator: McLean, Karen

A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

Principal Investigator: George, Saby

Phase 1 study of venetoclax/azacitidine or venetoclax in combination with ziftomenib (KO-539) or standard induction cytarabine/daunorubicin (7+3) chemotherapy in combination with ziftomenib for the treatment of patients with acute myeloid leukemia

Principal Investigator: Wang, Eunice S

MedSupport: A Novel Multilevel Intervention to Identify and Address Barriers to Pediatric Medication Adherence

Principal Investigator: Kelly, Kara M

I Can Join the Fight Against Cancer: An intervention to programmatically build grassroots actions to reduce the cancer burden.

Principal Investigator: Bouchard, Elizabeth G

A FIRST-IN-HUMAN, PHASE 1, DOSE ESCALATION STUDY OF SGR-2921 AS MONOTHERAPY IN SUBJECTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROME

Principal Investigator: Wang, Eunice S

A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP Compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2)

Principal Investigator: Hernandez-Ilizaliturri, Francisco J

A Phase I, Dose Escalation and Dose Expansion, Safety and Tolerability Study of onCARlytics (CF33-CD19), Administered Intravenously or Intratumorally in Combination with Blinatumomab in Adults with Advanced or Metastatic Solid Tumors (OASIS)

Principal Investigator: Fountzilas, Christos

(ARST2031) A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO…

Principal Investigator: Gupta, Ajay

An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma

Principal Investigator: Hernandez-Ilizaliturri, Francisco J

A Phase 2, Open-label, Multicenter Study Investigating RP2 Oncolytic Immunotherapy in Combination with Second-line Therapy in Patients with Locally Advanced Unresectable, Recurrent and/ or Metastatic Hepatocellular Carcinoma

Principal Investigator: Iyer, Renuka V

A Phase 2 Study of Futibatinib in Combination with PD-1 Antibody-based Standard of Care Therapy in Patients with Solid Tumors

Principal Investigator: Mukherjee, Sarbajit

Phase II Randomized, Double Blind, Placebo-Controlled Trial of the Broccoli Seed and Sprout Extract (BSSE), Avmacol ES, to Evaluate Sustained Detoxification of Tobacco Carcinogens in Heavy Smokers

Principal Investigator: Reid, Mary E

A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)

Principal Investigator: Hernandez-Ilizaliturri, Francisco J

A phase 1b dose optimization study of sovilnesib (an oral KIF18A inhibitor) in subjects with advanced high grade serous ovarian cancer

Principal Investigator: McLean, Karen

KOMEN-008: A Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia

Principal Investigator: Wang, Eunice S

(AALL2121) A Phase 2 study of revumenib (SNDX-5613) in combination with chemotherapy for patients with relapsed or refractory KMT2A-rearranged infant leukemia

Principal Investigator: Mallhi, Kanwal

B-Adrenergic Blockade with Chemotherapy and Checkpoint Inhibition in PD-L1
Positive Metastatic Triple Negative Breast Cancer

Principal Investigator: Gandhi, Shipra

Phase 1/2 UMBRELLA trial evaluating isatuximab with or without dexamethasone in combination with novel agents in relapsed or refractory multiple myeloma (RRMM)

Principal Investigator: Hillengass, Jens

A Phase 3 Randomized Clinical Study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008)

Principal Investigator: Niu, Alex

A Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes [TIL]) in participants with previously treated advanced endometrial cancer

Principal Investigator: Mager, Katherine